Get the Stockscreener App
66.45
0.29%
0.14
Dexcom Inc stock is traded at $66.45, with a volume of 2.10M.
It is up +0.29% in the last 24 hours and up +2.19% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
See More
Previous Close:
$66.31
Open:
$65.65
24h Volume:
2.10M
Relative Volume:
0.42
Market Cap:
$25.58B
Revenue:
$4.66B
Net Income/Loss:
$836.30M
P/E Ratio:
31.75
EPS:
2.093
Net Cash Flow:
$1.08B
1W Performance:
-5.92%
1M Performance:
+2.19%
6M Performance:
-12.75%
1Y Performance:
-6.01%
1-Day Range:
$65.17
$66.60
1-Week Range:
$65.17
$69.86
52-Week Range:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
66.47 | 25.52B | 4.66B | 836.30M | 1.08B | 2.093 |
|
ABT
Abbott Laboratories
|
108.72 | 191.58B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
339.10 | 132.33B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
87.81 | 114.23B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
68.08 | 103.32B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
84.38 | 49.42B | 6.07B | 1.06B | 1.34B | 1.8063 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Initiated | Evercore ISI | In-line |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
Swiss National Bank Trims Stake in DexCom by 4.8% - National Today
Swiss National Bank Sells 56,600 Shares of DexCom, Inc. $DXCM - MarketBeat
Mackenzie Financial Corp Raises Position in DexCom, Inc. $DXCM - MarketBeat
Capital Research Global Investors Trims Holdings in DexCom, Inc. - National Today
Capital Research Global Investors Cuts Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
Analysts Set DexCom, Inc. (NASDAQ:DXCM) PT at $85.18 - National Today
Sands Capital Management LLC Lowers Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
WINTON GROUP Ltd Lowers Position in DexCom, Inc. $DXCM - MarketBeat
Citigroup Adjusts Price Target on DexCom to $84 From $77, Maintains Buy Rating - marketscreener.com
First Trust Advisors LP Boosts Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026 - Morningstar
Dexcom G7 study: weight benefits and fewer ketoacidosis hospital visits - Stock Titan
Investigation announced for Long-Term Investors in shares of DexCom, Inc. (NASDAQ: DXCM) - openPR.com
2 Growth Stocks to Hold for the Next Decade - The Motley Fool
DexCom Inc (NASDAQ:DXCM): A Prime Example of Growth at a Reasonable Price - ChartMill
Here's Why DexCom (DXCM) is a Strong Growth Stock - Yahoo Finance
DexCom (NASDAQ:DXCM) Given Buy Rating at BTIG Research - MarketBeat
Demystifying DexCom: Insights From 12 Analyst Reviews - Benzinga
Rathbones Group PLC Reduces DexCom Stake by 79.9% - National Today
Rathbones Group PLC Has $9.32 Million Position in DexCom, Inc. $DXCM - MarketBeat
Korea Investment CORP Has $51.79 Million Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
Bell Asset Management Ltd Buys Shares of 31,448 DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. $DXCM Shares Sold by Alamar Capital Management LLC - MarketBeat
DexCom, Inc. (NASDAQ:DXCM) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Can DexCom Inc. stock resist market sell offs2026 Opening Moves & Smart Investment Allocation Tips - Naître et grandir
Neuberger Berman Group LLC Buys 324,849 Shares of DexCom, Inc. $DXCM - MarketBeat
Blair William & Co. IL Lowers Holdings in DexCom, Inc. $DXCM - MarketBeat
Bio-Techne, Bruker, DexCom, STERIS, and Teleflex Shares Plummet, What You Need To Know - Yahoo Finance
A Look At Dexcom (DXCM) Valuation After Recent Share Price Swings - Yahoo Finance
Mizuho raises DexCom (DXCM) price target to $90 from $78 after earnings beat - MSN
Is DexCom Stock Underperforming the Nasdaq? - Yahoo Finance
Fisher Asset Management LLC Sells 23,056 Shares of DexCom, Inc. $DXCM - MarketBeat
DexCom: Gaining Favor, With Useful Tailwinds To Support It Even Further (NASDAQ:DXCM) - Seeking Alpha
Picton Mahoney Asset Management Acquires 26,106 Shares of DexCom, Inc. $DXCM - MarketBeat
CI Investments Inc. Increases Position in DexCom, Inc. $DXCM - MarketBeat
Elo Mutual Pension Insurance Co Has $3.66 Million Stock Position in DexCom, Inc. $DXCM - MarketBeat
Dexcom Executive Chairman Kevin Sayer Returns From Leave - The Globe and Mail
How Adding Google’s Rick Osterloh To Dexcom’s Board (DXCM) Could Reframe Its Investment Story - simplywall.st
Nasdaq 100 Stock Outlook 2026: DexCom vs. Comcast & Warner Bros. DiscoveryNews and Statistics - IndexBox
Champlain Investment Partners LLC Decreases Stake in DexCom, Inc. $DXCM - MarketBeat
Intech Investment Management Reduces DexCom Stake - National Today
Rafferty Asset Management Boosts DexCom Holdings - National Today
Dexcom Launches First Nationwide Search for College Athletes With Diabetes to Join Season Four of Dexcom U - Quantisnow
TD Asset Management Boosts DexCom Stake by 16% - National Today
DexCom, Inc. (DXCM) Stock Analysis: 16.91% Potential Upside Amid Robust Growth Metrics - DirectorsTalk Interviews
DexCom (DXCM) Announces Leadership Transition and Compensation D - GuruFocus
American Century Companies Inc. Reduces DexCom Stake - National Today
Kevin Sayer returns as Dexcom (NASDAQ: DXCM) executive chairman - Stock Titan
DexCom, Inc. $DXCM Shares Sold by American Century Companies Inc. - MarketBeat
DexCom, Inc. Announces Board Changes, Effective March 2, 2026 - marketscreener.com
TD Asset Management Inc Buys 44,770 Shares of DexCom, Inc. $DXCM - MarketBeat
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.28%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):